Immunicum has been granted an Orphan Drug Designation (ODD) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST). This designation confirms the need and potential for ilixadencel as a

Elicera Therapeutics has been awarded funding from the European Innovation Council (EIC) Accelerator Programme. The grant is sufficient to fully fund Elicera’s planned clinical phase I/II-study evaluating its CAR T-cell

Asgard Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent related to the method of reprogramming cells towards the dendritic cell fate.

The Board of Directors of Spago Nanomedical has resolved to carry out a rights issue with preferential rights for existing shareholders of up to 61.8 MSEK before issue costs. Four

Xbrane Biopharma has withdrawn the BLA (Biologics License Application) for its investigational biosimilar candidate to Lucentis after receiving feedback from the FDA that complementary information is required for the FDA

Calliditas Therapeutics has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional

The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia, Clinical Laboratory licensure. The licensure allows physicians in Rhode Island to order the IMMray PanCan-d

Hansa Biopharma has announces that the Swiss Agency for Therapeutic Products (Swissmedic) has granted temporary marketing authorization for Idefirix in adult patients with a positive crossmatch against an available organ

BioInvent International receives a milestone payment from Bayer/Hope Medicine following clinical progression of an out-licensed antibody. BioInvent receives EUR 500,000 following the enrollment of the first patient in a Phase

Ilya Pharma has announced that FDA have cleared an IND for its lead candidate ILP100-Topical and that the company is immediately accelerating preparations for large adaptive Phase 2 study, designed

Ultimovacs has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application on the use of vaccine-checkpoint inhibitor combinations to treat

Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis. Founded in 2010,

The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development

Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors. “I believe

The US biotech company, focusing om messenger RNA therapeutics and vaccines, has announced plans to expand its commercial footprint in Europe across six additional countries. The announcement reinforces Moderna’s commitment